Expert Interview
A Second View: Discussing the Phase 3 topline results from study 502 looking at Lumateperone in patients with major depressive disorder
Ticker(s): ITCIInstitution: Self-employed
- treats around 50 patients with PPD.
- I am familiar with the recent approval of ZURZUVAE (zuranolone) for PPD and the Phase 3 SKYLARK study in PPD.
- also treats lots of patients with MDD.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
